No Clinically Significant Drug Interaction Between Hydroxyurea and Tamsulosin
There is no documented drug interaction between hydroxyurea (Hydrea) and tamsulosin, and these medications can be safely used together.
Evidence Base
The available evidence does not identify any pharmacokinetic or pharmacodynamic interactions between these two agents:
Tamsulosin Drug Interactions (FDA Label)
The FDA-approved tamsulosin label 1 comprehensively details drug interactions, focusing on:
- CYP450 metabolism: Tamsulosin is metabolized primarily by CYP3A4 and CYP2D6. Significant interactions occur with strong inhibitors (ketoconazole increases exposure 2.2-2.8-fold; paroxetine increases exposure 1.3-1.6-fold)
- Alpha-blockers: Potential additive hypotensive effects with other alpha-adrenergic blocking agents
- PDE5 inhibitors: Caution due to vasodilatory effects
- Specific agents tested: Cimetidine, warfarin, nifedipine, atenolol, enalapril, digoxin, theophylline, and furosemide
Hydroxyurea is notably absent from this comprehensive list of evaluated interactions.
Hydroxyurea Drug Interactions
The guideline literature on hydroxyurea use in various conditions 2, 3, 4, 5 does not mention tamsulosin or alpha-blockers as interacting medications. Hydroxyurea's mechanism (ribonucleotide reductase inhibition) and metabolism profile do not overlap with tamsulosin's pharmacology.
Clinical Context
Real-world use supports safety:
- A 1999 study 6 specifically addressed managing hypertension and benign prostatic hyperplasia (BPH) in elderly patients, recommending tamsulosin with various antihypertensives without mentioning hydroxyurea as a contraindication
- Multiple studies on hydroxyurea safety in sickle cell disease 7, 8 and thalassemia 9 with long-term follow-up (up to 22 years) report adverse events comprehensively but do not identify interactions with urologic medications
Clinical Implications
These medications can be co-administered without dose adjustment or special monitoring beyond what is standard for each drug individually:
- For tamsulosin: Monitor for orthostatic hypotension, particularly when initiating therapy or combining with other antihypertensives
- For hydroxyurea: Continue standard monitoring (CBC with differential, renal/hepatic function) per indication-specific guidelines 2, 4, 5
Common Pitfall to Avoid
Do not confuse the lack of documented interaction with lack of safety data. The absence of interaction is supported by:
- Different metabolic pathways (hydroxyurea is not significantly metabolized by CYP450 enzymes)
- Different mechanisms of action
- Comprehensive FDA interaction studies for tamsulosin that would have identified clinically relevant interactions
- Decades of clinical experience with both agents without reported interactions